Truist Securities increased its price target for Medtronic plc (MDT) to $110 from $103, maintaining a Hold rating, following strong fiscal second-quarter revenue growth. The growth was primarily driven by the company's Pulsed Field Ablation (PFA) technology, which led to a 71% year-over-year organic rise in sales for the cardiac ablation solutions division. Despite a revenue beat, an operating margin miss and increased reinvestment limited upside growth and profit acceleration.

美敦力

<p>Truist Securities 將美敦力（Medtronic plc，股票代碼：MDT）的目標股價從 103 美元上調至 110 美元，維持持有評級，此次調整是基於其強勁的財政第二季度收入增長。該增長主要得益於公司的脈衝場消融（PFA）技術，使心臟消融解決方案部門的銷售同比增長了 71%。儘管收入超出預期，但運營利潤率未達預期以及增加的再投資限制了上行增長和利潤加速</p>

美敦力（MDT）目標價格被上調，因為 PFA 技術推動了第二季度的收入增長